CMP Stock Overview
Engages in the research, development, manufacture, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Compumedics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.30 |
| 52 Week High | AU$0.41 |
| 52 Week Low | AU$0.22 |
| Beta | 1.13 |
| 1 Month Change | 15.09% |
| 3 Month Change | 3.39% |
| 1 Year Change | -22.78% |
| 3 Year Change | -21.79% |
| 5 Year Change | -55.15% |
| Change since IPO | -65.73% |
Recent News & Updates
Recent updates
This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks Appropriate
Oct 24
Further Upside For Compumedics Limited (ASX:CMP) Shares Could Introduce Price Risks After 38% Bounce
Jun 17Returns On Capital Signal Difficult Times Ahead For Compumedics (ASX:CMP)
Mar 07We Think Compumedics (ASX:CMP) Has A Fair Chunk Of Debt
Nov 03Is Compumedics (ASX:CMP) A Risky Investment?
May 27Compumedics (ASX:CMP) Could Be At Risk Of Shrinking As A Company
Jan 25Some Shareholders May Object To A Pay Rise For Compumedics Limited's (ASX:CMP) CEO This Year
Oct 19Compumedics (ASX:CMP) Seems To Use Debt Quite Sensibly
Oct 14Is Compumedics (ASX:CMP) Using Debt Sensibly?
May 02Compumedics (ASX:CMP) May Have Issues Allocating Its Capital
Dec 08Compumedics (ASX:CMP) Will Want To Turn Around Its Return Trends
Aug 09Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt Burden
Jun 10Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)
May 06These 4 Measures Indicate That Compumedics (ASX:CMP) Is Using Debt Extensively
Feb 25How Much Did Compumedics'(ASX:CMP) Shareholders Earn From Share Price Movements Over The Last Year?
Dec 01Shareholder Returns
| CMP | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 7.0% | 2.9% | 1.9% |
| 1Y | -22.8% | 7.4% | 9.7% |
Return vs Industry: CMP underperformed the Australian Medical Equipment industry which returned 7.4% over the past year.
Return vs Market: CMP underperformed the Australian Market which returned 9.7% over the past year.
Price Volatility
| CMP volatility | |
|---|---|
| CMP Average Weekly Movement | 7.2% |
| Medical Equipment Industry Average Movement | 9.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in AU Market | 16.5% |
| 10% least volatile stocks in AU Market | 2.9% |
Stable Share Price: CMP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CMP's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 155 | David Burton | www.compumedics.com.au |
Compumedics Limited engages in the research, development, manufacture, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the United States, and Europe. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients’ physiological data; Somté PSG; Okti; Grael PSG; Grael 4K PSG; Falcon PSG; Falcon HST; Somté, an investigative tool; Siesta 802; and Somté PSG. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, an portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device.
Compumedics Limited Fundamentals Summary
| CMP fundamental statistics | |
|---|---|
| Market cap | AU$57.89m |
| Earnings (TTM) | -AU$338.00k |
| Revenue (TTM) | AU$50.26m |
1.1x
P/S Ratio-165.8x
P/E RatioIs CMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMP income statement (TTM) | |
|---|---|
| Revenue | AU$50.26m |
| Cost of Revenue | AU$23.65m |
| Gross Profit | AU$26.61m |
| Other Expenses | AU$26.95m |
| Earnings | -AU$338.00k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0018 |
| Gross Margin | 52.94% |
| Net Profit Margin | -0.67% |
| Debt/Equity Ratio | 38.3% |
How did CMP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 07:31 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Compumedics Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ian Martin | New Street Research LLP |
| Paul Jensz | PAC Partners Securities Pty. Ltd. |
| Stephen Scott | Taylor Collison Limited |